Status:
UNKNOWN
Outcome of Treatment of Uveitis With Biologic Drugs in Resistant Cases Vogt-koyanagi-Harada Disease
Lead Sponsor:
Assiut University
Conditions:
Uveitis
Eligibility:
All Genders
18-65 years
Brief Summary
* Reviewing the characteristics of patients with uveitis caused by Vogt-Koyanagi-Harada Syndrome treated at Assiut University Hospital at the Department of Ophthalmology and Department of Rheumatology...
Detailed Description
Uvea (Latin for grape) is the middle vascular coat of the eyeball. Strictly speaking, uveitis is defined as inflammation of the uvea, but often the inflammatory process involves adjacent intraocular s...
Eligibility Criteria
Inclusion
- Uveitis with clinical features of Vogt-Koyanaga-Harada Syndrome.
- A follow-up and assessment at least twelve months from the start of treatment.
Exclusion
- Exclusion of other infectious and non-infectious uveiticuveitis etiologies that may mimic the given clinical presentation of autoimmune uveitis;
- The presence of contraindication to treatment with biologic drugs e.g. active or latent tuberculosis, viral hepatitis and demyelinating diseases.
Key Trial Info
Start Date :
April 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05349747
Start Date
April 30 2022
End Date
August 1 2024
Last Update
April 27 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.